Mayo Clinic to collaborate with Eric Lefkofsky’s Tempus
January 4th, 2017
Eric Lefkofsy’s Tempus technology firm is collaborating with the Mayo Clinic, considered the preeminent health-care facility in the world.
Chicago-based Tempus uses analytics to help doctors customize treatment for cancer patients. During the past year, Tempus has joined forces with hospitals and medical centers around the world to expand its data all in an effort to cure cancer.
Tempus will provide molecular sequencing and analysis for 1,000 Mayo Clinic patients participating in two research projects: immunotherapy in lung cancer, melanoma, bladder cancer, breast cancer, and lymphoma, and endocrine therapy in advanced breast cancer.
Researchers say the goal is to improve patient quality of life by limiting exposure to ineffective drugs and unnecessary toxicity and, most importantly, to improve survival rates.
A few months ago, Lefkofsky, the co-founder and CEO of Tempus, talked about what propelled him to start the business that will be his legacy.
“You start a company when you believe you’ve identified a big problem — a problem painful enough that you want to spend time fixing it,” he said.
In a release this week, Lefkofsky said, “Technology has made incredible advances over the last two decades, but it has not yet fully permeated the healthcare system. We are excited to bring Tempus’ operating system and analytical technology to Mayo for the benefit of physicians and patients in their battle with cancer.”
Other medical institutions working with Tempus include Northwestern University’s Lurie Comprehensive Cancer Center, Rush University Medical Center, a clinical trial group at University of Chicago and University of Pennsylvania’s Abramson Cancer Center.